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To the Editor,
We read with interest the paper by Lippi et al. [1] dealing 
with serum indices. Serum indices, also conventionally 
known as HIL (hemolysis, icterus, lipemia), are simple, 
rapid, automated and inexpensive spectrophotometric 
measures widely used for assessing sample quality before 
clinical chemistry testing [2]. Concerning the use of the 
L-index (an index reflecting sample turbidity), the authors 
regarded the L-index as a surrogate measure for screening 
of hypertriglyceridemia.
In this respect, the enzymatic triglyceride test is 
regarded as a kind of clinical reference, whereas the turbid-
ity is regarded as not specific for lipids [3]. The introduction 
of enzymatic triglyceride testing in the 1970s created the 
so-called “glycerol-error” in triglyceride testing. One mil-
ligram of free glycerol (molar mass: 92 g/mol) erroneously 
produces an absorbance equivalent with ±9 mg of triglyc-
erides (molar mass: 885 g/mol). Even when this analytical 
error can be easily corrected, the vast majority of clinical 
laboratories have been using the non-glycerol-blanked 
tests [4]. Due to the limited demand, these glycerol-
blanked tests will no longer be on the in vitro diagnostics 
market in the near future. The so-called false-negative pre-
diction of hypertriglyceridemia by the L-index should be 
interpreted with caution when data points are outside the 
95% confidence interval of the log(triglycerides)/L-index 
regression equation. Metabolic diseases such as glycerol 
kinase deficiency and glycerol-3-phosphate dehydroge-
nase 1 deficiency [5–7] can be detected by the combination 
of a low L-index and an apparent “hypertriglyceridemia” 
[8]. The apparent “false-negative” screening result based 
on the normal L-index in combination with an “increased” 
triglyceride value is actually a false-positive triglyceride 
result in these cases! The patient is often subjected to both 
aggressive nutritional and combination lipid-lowering 
drug treatment, which is ineffective. Eliminating inter-
pretation errors in false hypertriglyceridemia and avoid-
ing unnecessary treatment improve the benefit-to-harm 
ratio in triglyceride testing. Due to their size difference, 
triglyceride-containing plasma lipoproteins show a broad 
variation in their light scattering properties [9]. This light 
scattering is the physical basis of the L-index, whereas the 
triglyceride concentration results are independent of the 
size of the triglyceride-containing particles. Therefore, the 
ratio between the logarithmic transformed values of the 
triglycerides and the L-index is an estimate of the average 
particle size of triglyceride-containing particles [8].
In conclusion, the L-index should not solely be 
regarded as a screening test for hypertriglyceridemia or as 
a measure to verify the fasting state of a blood specimen, 
but as also that contains other clinically relevant informa-
tion. Apart from the detection of rare metabolic disorders, 
in particular the log(triglycerides)/L-index may be useful 
in this respect. These insights should also persuade man-
ufacturers and laboratorians to embark on a validation 
process for the HIL indices [2].
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